Study shows benefits of CGM in adults with diabetes who take multiple daily injections

DexCom, Inc., the leader in continuous glucose monitoring (CGM) for people with diabetes, is presenting important clinical data for patients with type 1 and type 2 diabetes, at the American Diabetes Association's 77th Scientific Sessions, June 9-13 in San Diego, California.

The new data is the result of combined type 1 and type 2 cohorts from the DIaMonD study (Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes) and demonstrates the impact of CGM on A1C, hyperglycemia and hypoglycemia in adults with either type 1 or type 2 diabetes who choose to take multiple daily injections of insulin in lieu of other methods of insulin delivery. The study showed DexCom CGM System users achieved a 0.9 percent average A1C reduction after 24 weeks of regular use, compared to 0.5 percent in the Usual Care group that relied only on fingerstick blood glucose measurements. The benefits in glycemic control were seen even in study participants using CGM that had large decreases in the number of fingersticks.

Additional highlights include:

• Strong adherence to CGM in adults with both type 1 and type 2 diabetes regardless of age, education or numeracy.
• Ninety-three percent were using CGM more than six days a week in month six.
• Consistent A1C reductions in all subgroups.
• Time in range increased, while times in hypoglycemia and hyperglycemia decreased.
• Patients with both type 1 and type 2 diabetes frequently interact with their CGM display device, providing greater glucose awareness and better informing their diabetes management decisions.

"This new data represents another important milestone in a blockbuster year for the advancement of diabetes management," said Kevin Sayer, President and CEO of DexCom. "As the first and only therapeutic CGM approved by Medicare for patients age 65 or older, DexCom G5 Mobile is setting a new standard of care for a wide spectrum of patients."